ClinicaliQ Trial Snapshot
- Transition to KPL-387 Monotherapy Dosing & Administration Study — Recruiting • Phase II • Cardiology / Cardiovascular • NCT07288216.
- What is being tested: KPL-387 monotherapy dosing regimens designed to safely transition patients from established pericarditis treatments, evaluating efficacy and safety profiles during this transition phase.
- Patient eligibility overview: Adults with recurrent pericarditis that is well-controlled on current standard therapies are eligible; the study focuses on those ready to switch to KPL-387 as a potential monotherapy alternative.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The primary objective of this study is to characterize the efficacy and safety of dosing regimens used to transition from prior pericarditis therapies to KPL-387 monotherapy in participants with well-controlled recurrent pericarditis on standard therapies.
Eligibility Snapshot
- Key Inclusion Criteria: * Has well-controlled recurrent pericarditis (i.e., including having CRP < 0.5 mg/dL within 14 days of Baseline and a pericarditis pain NRS score ≤ 3 at Baseline) * Has a documented history of CRP elevation (> 1 mg/dL) associated with at least one prior acute pericarditis episode, whether the incident event or any pericarditis recurrence * Has received treatment for RP for at least 3 months prior to Baseline with standard therapy(ies) and is currently on a stable dosing regimen including NSAIDs and/or colchicine, and/or glucocorticoids or an IL-1 pathway inhibitor (anakinra or rilonacept). Key
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.